Cumulative incidence of sustained AKI in one year was 17.8% in the anti-VEGF group, which was similar with the one-year incidence of AKI (19.2%) in patients with metastatic colorectal cancer treated with chemotherapy combined with bevacizumab [14]. This evidence concerns the gene VEGFA and acute kidney injury.